Perseus Biomics

The computed 12-month bankruptcy probability of Perseus Biomics is 2.2% (moderate). The annual accounts of Perseus Biomics for financial year 2025 show a net loss of 54% of the equity at the start of that year. The 2025 annual accounts show equity of €2.1m and a net result of -€2.5m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 45% of 60 sector peers (NACE 21, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.